Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Preventive Model for Muscle Injuries: A Novel Approach based on Learning Algorithms.
López-Valenciano A, Ayala F, Puerta JM, DE Ste Croix MBA, Vera-Garcia FJ, Hernández-Sánchez S, Ruiz-Pérez I, Myer GD. López-Valenciano A, et al. Among authors: puerta jm. Med Sci Sports Exerc. 2018 May;50(5):915-927. doi: 10.1249/MSS.0000000000001535. Med Sci Sports Exerc. 2018. PMID: 29283933 Free PMC article.
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity.
Moreno-Arciniegas A, García A, Kelm M, D'Amore F, da Silva MG, Sánchez-González J, Sánchez PL, López-Fernández T, Córdoba R, Asteggiano R, Camus V, Smink J, Ferreira A, Kersten MJ, Bolaños N, Escalera N, Pacella E, Gómez-Talavera S, Quesada A, Rosselló X, Ibanez B; RESILIENCE Trial Investigators. Moreno-Arciniegas A, et al. Eur J Heart Fail. 2024 Oct;26(10):2213-2222. doi: 10.1002/ejhf.3395. Epub 2024 Aug 30. Eur J Heart Fail. 2024. PMID: 39212445 Clinical Trial.
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Sancho JM, Marín-Niebla A, Fernández S, Capote FJ, Cañigral C, Grande C, Donato E, Zeberio I, Puerta JM, Rivas A, Pérez-Ceballos E, Vale A, Martín García-Sancho A, Salar A, González-Barca E, Teruel A, Pastoriza C, Conde-Royo D, Sánchez-García J, Barrenetxea C, Arranz R, Hernández-Rivas JÁ, Ramírez MJ, Jiménez A, Rubio-Azpeitia E. Sancho JM, et al. Among authors: puerta jm. Int J Hematol. 2022 Sep;116(3):381-392. doi: 10.1007/s12185-022-03367-z. Epub 2022 May 13. Int J Hematol. 2022. PMID: 35551632 Free PMC article.
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients.
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, Sánchez-Pina JM, Collado R, Díaz-González A, Angona A, Sagüés M, García-Gutiérrez V, Boqué C, Osorio S, Vallansot R, Palomera L, Mendizábal A, Casado LF, Pérez-Encinas M, Pérez-López R, Ferrer-Marín F, Sánchez-Guijo F, García C, Heras NL, López-Lorenzo JL, Cervantes F, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). Hernández-Boluda JC, et al. Among authors: puerta jm. Blood Cancer J. 2018 Dec 2;8(10):91. doi: 10.1038/s41408-018-0125-0. Blood Cancer J. 2018. PMID: 30504932 Free PMC article.
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC). García-Gutiérrez V, et al. Among authors: puerta jm. Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16. Ann Hematol. 2019. PMID: 30446802 Clinical Trial.
A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.
García-Gutiérrez V, Gómez-Casares MT, Puerta JM, Alonso-Domínguez JM, Osorio S, Hernández-Boluda JC, Collado R, Ramírez MJ, Ibáñez F, Martín ML, Rodríguez-Gambarte JD, Martínez-Laperche C, Gómez M, Fiallo DV, Redondo S, Rodríguez A, Ruiz-Nuño C, Steegmann JL, Jiménez-Velasco A; Spanish Group of Chronic Myeloid Leukemia (GELMC). García-Gutiérrez V, et al. Among authors: puerta jm. PLoS One. 2017 Mar 9;12(3):e0173532. doi: 10.1371/journal.pone.0173532. eCollection 2017. PLoS One. 2017. PMID: 28278193 Free PMC article.
Early mortality in multiple myeloma: the time-dependent impact of comorbidity: A population-based study in 621 real-life patients.
Ríos-Tamayo R, Sáinz J, Martínez-López J, Puerta JM, Chang DY, Rodríguez T, Garrido P, de Veas JL, Romero A, Moratalla L, López-Fernández E, González PA, Sánchez MJ, Jiménez-Moleón JJ, Jurado M, Lahuerta JJ. Ríos-Tamayo R, et al. Among authors: puerta jm. Am J Hematol. 2016 Jul;91(7):700-4. doi: 10.1002/ajh.24389. Epub 2016 Apr 28. Am J Hematol. 2016. PMID: 27074204 Free article.
14 results